Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) EBT Margin (2021 - 2024)

Amylyx Pharmaceuticals has reported EBT Margin over the past 4 years, most recently at 41442.77% for Q4 2024.

  • Quarterly results put EBT Margin at 41442.77% for Q4 2024, down 4145129.0% from a year ago — trailing twelve months through Sep 2025 was 23874.21% (down 2371915.0% YoY), and the annual figure for FY2024 was 0.43%, down 1469.0%.
  • EBT Margin for Q4 2024 was 41442.77% at Amylyx Pharmaceuticals, down from 17476.92% in the prior quarter.
  • Over the last five years, EBT Margin for AMLX hit a ceiling of 589.6% in Q4 2022 and a floor of 41442.77% in Q4 2024.
  • Median EBT Margin over the past 4 years was 133.74% (2024), compared with a mean of 7589.45%.
  • Biggest five-year swings in EBT Margin: surged 987210bps in 2023 and later plummeted -4145129bps in 2024.
  • Amylyx Pharmaceuticals' EBT Margin stood at 8120.0% in 2021, then soared by 107bps to 589.6% in 2022, then plummeted by -99bps to 8.53% in 2023, then plummeted by -486227bps to 41442.77% in 2024.
  • The last three reported values for EBT Margin were 41442.77% (Q4 2024), 17476.92% (Q3 2024), and 7106.55% (Q2 2024) per Business Quant data.